Disease · MONDO_0016064

cleft palate

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. cleft palate. Diseases, record MONDO_0016064. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016064

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: cleft palate; Open Targets
Open Targets ID: MONDO_0016064; Open Targets
Other names: Cleft Palates, Cleft hard and soft palate, Cleft of hard and soft palate, Cleft of palate, Cleft roof of mouth, Palate, Cleft, Palates, Cleft, palatoschisis, uranostaphyloschisis; Open Targets
Disease Ontology: DOID:674; Disease Ontology
MeSH: D002972; MeSH
NCI Thesaurus: C87069; NCI Thesaurus
Orphanet: ORPHA:2014; Orphanet
Highest stage of its drugs: Phase 2/3, for 2 of its 6 drugs, from ClinicalTrials.gov; Open Targets

Drugs6

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BUPIVACAINE	CHEMBL1098	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
LEVOBUPIVACAINE	CHEMBL1201193	Small molecule	Phase 2/3	ClinicalTrials.gov	1	1	1	Drugs and targets
DEXMEDETOMIDINE	CHEMBL778	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
KETAMINE	CHEMBL742	Small molecule	Phase 1	ClinicalTrials.gov	1	1	1	Drugs and targets
ACETAMINOPHEN	CHEMBL112	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets
NALBUPHINE	CHEMBL895	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets18

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
SCN4A	Sodium channel protein type 4 subunit alpha	2	Sodium channel protein type IV alpha subunit blocker	Phase 2/3	https://conductscience.org/library/genes/6329	Drugs and targets
ADRA2A	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 1	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 1	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha-2	1	Adrenergic receptor alpha-2 agonist	Phase 1	https://conductscience.org/library/genes/152	Drugs and targets
FAAH	Fatty-acid amide hydrolase 1	1	Anandamide amidohydrolase inhibitor	Unknown	https://conductscience.org/library/genes/2166	Drugs and targets
GRIN1	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 1	https://conductscience.org/library/genes/2902	Drugs and targets
GRIN2A	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 1	https://conductscience.org/library/genes/2903	Drugs and targets
GRIN2B	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 1	https://conductscience.org/library/genes/2904	Drugs and targets
GRIN2C	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 1	https://conductscience.org/library/genes/2905	Drugs and targets
GRIN2D	Glutamate [NMDA] receptor	1	Glutamate [NMDA] receptor negative allosteric modulator	Phase 1	https://conductscience.org/library/genes/2906	Drugs and targets

1 to 10 of 18

See all 18 targets

Trials4

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01500109	Efficacy of Oral Versus Intravenous Acetaminophen for Primary Pediatric Cleft Palate Repair	Not applicable	45	2015-04-01	Cleft Palate	ACETAMINOPHEN	Its record names the disease	ClinicalTrials.gov
NCT02923869	Comparative Study Between Levobupivacaine and Bupivacaine for Nerve Block During Pediatric Primary Cleft Palate Surgery	Phase 2/3	60		Recovery After Cleft Palate Surgery	BUPIVACAINE, LEVOBUPIVACAINE	Its record names the disease	ClinicalTrials.gov
NCT06100315	Nalbuphine as Adjuvant During Bilateral Suprazygomatic Maxillary Nerve Block for Pediatric Cleft Palate Repair	Phase 2/3	60		Complication Following Peripheral Nerve Block	NALBUPHINE	Its record names the disease	ClinicalTrials.gov
NCT05402189	Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioid Based Anaesthesia in Cleft Palate Repair Ketodex Versus Opioids in Cleft Palate Repaire	Phase 1	50		Ketodex Versus Opioids Based Anaesthesia in Cleft Palate Repair	DEXMEDETOMIDINE, KETAMINE	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials2

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
31888322	RESULT	1	PubMed
20199610	RESULT	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0016064

GET https://conductscience.org/api/diseases/v1/MONDO_0016064/drugs

API reference For AI assistants